Tempest Therapeutics IncNASDAQ:TPST
- LAST PRICE3.3200
- TODAY'S CHANGE (%)0.0400 (1.2195%)
- Bid / Lots3.3300/ 2
- Ask / Lots3.3600/ 6
- Open / Previous Close3.3000 / 3.2800
- Day Range
- 52 Week Range
- Volume149,930
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TPST |
|---|---|---|
| 09:32 ET | 2437 | 3.345 |
| 09:34 ET | 1126 | 3.3111 |
| 09:36 ET | 1698 | 3.34 |
| 09:38 ET | 3499 | 3.34 |
| 09:39 ET | 243 | 3.39 |
| 09:41 ET | 1005 | 3.38 |
| 09:45 ET | 923 | 3.38 |
| 09:48 ET | 100 | 3.3793 |
| 09:50 ET | 181 | 3.37 |
| 09:52 ET | 1388 | 3.37 |
| 09:54 ET | 300 | 3.37 |
| 09:56 ET | 1309 | 3.36 |
| 09:57 ET | 100 | 3.36 |
| 10:01 ET | 661 | 3.37 |
| 10:06 ET | 1098 | 3.365 |
| 10:08 ET | 775 | 3.3652 |
| 10:12 ET | 299 | 3.36 |
| 10:14 ET | 1650 | 3.33 |
| 10:15 ET | 3534 | 3.34 |
| 10:17 ET | 783 | 3.34 |
| 10:19 ET | 2310 | 3.34 |
| 10:21 ET | 1375 | 3.3669 |
| 10:24 ET | 1000 | 3.349 |
| 10:28 ET | 200 | 3.33 |
| 10:32 ET | 1332 | 3.31 |
| 10:33 ET | 100 | 3.3 |
| 10:37 ET | 1882 | 3.2899 |
| 10:39 ET | 2200 | 3.3 |
| 10:44 ET | 100 | 3.3 |
| 10:46 ET | 560 | 3.31 |
| 10:48 ET | 267 | 3.3002 |
| 10:50 ET | 1108 | 3.2901 |
| 10:53 ET | 150 | 3.3 |
| 11:08 ET | 2300 | 3.3 |
| 11:09 ET | 508 | 3.31 |
| 11:11 ET | 1000 | 3.3001 |
| 11:13 ET | 100 | 3.31 |
| 11:15 ET | 2155 | 3.31 |
| 11:18 ET | 153 | 3.3101 |
| 11:20 ET | 624 | 3.32 |
| 11:26 ET | 2900 | 3.31 |
| 11:27 ET | 100 | 3.3088 |
| 11:29 ET | 700 | 3.305 |
| 11:31 ET | 1307 | 3.29 |
| 11:36 ET | 2237 | 3.308 |
| 11:38 ET | 500 | 3.3199 |
| 11:42 ET | 647 | 3.31 |
| 11:49 ET | 681 | 3.2901 |
| 11:58 ET | 100 | 3.294 |
| 12:00 ET | 1038 | 3.2895 |
| 12:02 ET | 500 | 3.2898 |
| 12:03 ET | 200 | 3.28 |
| 12:05 ET | 858 | 3.285 |
| 12:09 ET | 100 | 3.2882 |
| 12:16 ET | 1107 | 3.29 |
| 12:32 ET | 1670 | 3.294 |
| 12:34 ET | 100 | 3.29 |
| 12:43 ET | 200 | 3.2911 |
| 12:57 ET | 2300 | 3.3 |
| 01:01 ET | 1000 | 3.2985 |
| 01:03 ET | 100 | 3.295 |
| 01:06 ET | 300 | 3.29 |
| 01:08 ET | 100 | 3.29 |
| 01:12 ET | 250 | 3.2999 |
| 01:15 ET | 1013 | 3.29 |
| 01:17 ET | 100 | 3.29 |
| 01:19 ET | 20100 | 3.31 |
| 01:21 ET | 397 | 3.3004 |
| 01:26 ET | 200 | 3.3 |
| 01:28 ET | 2195 | 3.32 |
| 01:33 ET | 150 | 3.31 |
| 01:35 ET | 500 | 3.3199 |
| 01:37 ET | 100 | 3.31 |
| 01:39 ET | 2504 | 3.3 |
| 01:42 ET | 1000 | 3.3 |
| 01:48 ET | 1510 | 3.3001 |
| 01:53 ET | 3212 | 3.3036 |
| 01:55 ET | 100 | 3.3017 |
| 02:13 ET | 200 | 3.3 |
| 02:15 ET | 1853 | 3.3199 |
| 02:31 ET | 2438 | 3.31 |
| 02:33 ET | 100 | 3.32 |
| 02:44 ET | 500 | 3.32 |
| 02:51 ET | 604 | 3.319 |
| 02:58 ET | 100 | 3.32 |
| 03:00 ET | 1255 | 3.33 |
| 03:12 ET | 1100 | 3.325 |
| 03:18 ET | 100 | 3.3202 |
| 03:20 ET | 1328 | 3.3299 |
| 03:27 ET | 1520 | 3.33 |
| 03:30 ET | 116 | 3.33 |
| 03:32 ET | 5580 | 3.3301 |
| 03:34 ET | 543 | 3.325 |
| 03:36 ET | 200 | 3.325 |
| 03:38 ET | 200 | 3.32 |
| 03:39 ET | 100 | 3.31 |
| 03:41 ET | 2686 | 3.32 |
| 03:43 ET | 600 | 3.32 |
| 03:45 ET | 100 | 3.32 |
| 03:50 ET | 200 | 3.315 |
| 03:54 ET | 100 | 3.32 |
| 03:56 ET | 1250 | 3.3206 |
| 03:57 ET | 463 | 3.33 |
| 03:59 ET | 7612 | 3.32 |
Yesterday
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST), from 3:45PM ET on Friday May 31, 2024 by Dow Jones
3:45PM ET on Friday May 31, 2024 by Dow Jones
May 21, 2024
Tempest to Participate in Upcoming Investor Conferences, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones
8:00AM ET on Tuesday May 21, 2024 by Dow Jones
May 13, 2024
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 8:14AM ET on Monday May 13, 2024 by Dow Jones
8:14AM ET on Monday May 13, 2024 by Dow Jones
May 10, 2024
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 3:08PM ET on Friday May 10, 2024 by Dow Jones
3:08PM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:29PM ET on Thursday May 09, 2024 by Dow Jones
4:29PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tempest Therapeutics Inc | 73.8M | -1.9x | --- |
Annovis Bio Inc | 73.2M | -1.3x | --- |
Bioatla Inc | 72.7M | -0.6x | --- |
Benitec Biopharma Inc | 71.7M | -0.8x | --- |
Passage Bio Inc | 70.3M | -0.7x | --- |
vTv Therapeutics Inc | 70.2M | -2.7x | --- |
Company Information
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Contact Information
- Headquarters
- 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
- Phone
- 415-798-8589
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Raab
- President, Chief Executive Officer, Director
- Stephen Brady
- Executive Vice President, Chief Medical Officer
- Samuel Whiting
- Vice President - Strategy and Finance, Corporate Secretary
- Nicholas Maestas
- Independent Director
- Geoffrey Nichol
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $73.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.76 |
EPS | $-1.76 |
Book Value | $1.21 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
